Teladoc Health Balance Sheet Health
Financial Health criteria checks 5/6
Teladoc Health has a total shareholder equity of $1.4B and total debt of $994.9M, which brings its debt-to-equity ratio to 71.8%. Its total assets and total liabilities are $2.9B and $1.5B respectively.
Key information
71.80%
Debt to equity ratio
US$994.93m
Debt
| Interest coverage ratio | n/a |
| Cash | US$781.08m |
| Equity | US$1.39b |
| Total liabilities | US$1.47b |
| Total assets | US$2.86b |
Recent financial health updates
Is Teladoc Health (NYSE:TDOC) Using Too Much Debt?
Jan 27
Is Teladoc Health (NYSE:TDOC) A Risky Investment?
Oct 23Would Teladoc Health (NYSE:TDOC) Be Better Off With Less Debt?
Jun 04Recent updates
Teladoc Health, Inc.'s (NYSE:TDOC) 28% Dip In Price Shows Sentiment Is Matching Revenues
Feb 04Teladoc Health: Why Low Valuation Doesn't Equal A 'Buy' (Rating Downgrade)
Jan 21Teladoc Health, Inc. (NYSE:TDOC) Looks Inexpensive After Falling 26% But Perhaps Not Attractive Enough
Nov 23Teladoc Health, Inc. (NYSE:TDOC) Shares Could Be 49% Below Their Intrinsic Value Estimate
Aug 27The Teladoc Health, Inc. (NYSE:TDOC) Second-Quarter Results Are Out And Analysts Have Published New Forecasts
Jul 31Teladoc Health, Inc.'s (NYSE:TDOC) Low P/S No Reason For Excitement
Jun 18Teladoc: Back In The Doldrums After Another Tough Year (Rating Downgrade)
Apr 16Teladoc's Meltdown May Not Be Over Yet - Minimal Growth Opportunities
Mar 26
Integration Of Catapult Health And Global Partnerships Will Shape Future Success
Strategic focus on customer growth and tech innovation enhances service offerings, boosting visit volumes and revenue through visit-oriented arrangements.Teladoc Q4 Earnings: A Waiting Game For Investors (Rating Downgrade)
Feb 27Teladoc Health: Amazon To The Rescue, Potentially
Feb 19Teladoc Health, Inc. (NYSE:TDOC) Surges 32% Yet Its Low P/S Is No Reason For Excitement
Feb 08Is Teladoc Health (NYSE:TDOC) Using Too Much Debt?
Jan 27Teladoc: Minimal Growth Left As More Healthcare Players Leave/Diversify
Jan 10Teladoc: Attractive Valuation, But The Narrative Stalls
Dec 20Teladoc: Maybe This Goose Isn't Cooked Yet (Rating Upgrade)
Nov 27Teladoc Health, Inc. (NYSE:TDOC) Surges 40% Yet Its Low P/S Is No Reason For Excitement
Nov 26Teladoc Health, Inc. (NYSE:TDOC) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
Nov 02Is Teladoc Health (NYSE:TDOC) A Risky Investment?
Oct 23Teladoc: Double-Digit FCF Yield, Possible BetterHelp Transition
Oct 13Teladoc Health, Inc. (NYSE:TDOC) Surges 28% Yet Its Low P/S Is No Reason For Excitement
Sep 18Teladoc Health: Some Negative Things, But One Aspect That Makes Me Feel Positive
Sep 15Teladoc: Prospects Are Ready For Better Health
Sep 04Teladoc Post Q2 Earnings: Stick A Fork In This Stock - It's Nearly Done (For)
Aug 01Teladoc's Vital Signs: Why 5x FCF Means Stable Health (Rating Upgrade)
Jul 22Teladoc Health, Inc.'s (NYSE:TDOC) Revenues Are Not Doing Enough For Some Investors
Jul 17Teladoc Health: Weight Loss Management Could Help
Jul 01Would Teladoc Health (NYSE:TDOC) Be Better Off With Less Debt?
Jun 04Teladoc: Stock Likely To Be Range Bound Until Guidance Is Revised Upwards
May 31Teladoc: Huge Execution Problem
Apr 27Teladoc: Improving Business Trends (Rating Upgrade)
Apr 17Teladoc: Management Has A Lot To Prove To Gain Investor Confidence
Mar 25Teladoc Health, Inc.'s (NYSE:TDOC) 25% Dip In Price Shows Sentiment Is Matching Revenues
Mar 10Financial Position Analysis
Short Term Liabilities: TDOC's short term assets ($1.1B) exceed its short term liabilities ($404.7M).
Long Term Liabilities: TDOC's short term assets ($1.1B) exceed its long term liabilities ($1.1B).
Debt to Equity History and Analysis
Debt Level: TDOC's net debt to equity ratio (15.4%) is considered satisfactory.
Reducing Debt: TDOC's debt to equity ratio has increased from 9.1% to 71.8% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable TDOC has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: TDOC is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 35.1% per year.
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/12 11:05 |
| End of Day Share Price | 2026/03/12 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Teladoc Health, Inc. is covered by 37 analysts. 24 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | Argus Research Company |
| Vikram Kesavabhotla | Baird |
| Peter Warendorf | Barclays |